Лечение острого миелоидного лейкоза у детей

acute myeloid leukemia in children, treatment

1. Choi S.I., Simone J.V. Acute nonlymphocytic leukemia in 171 children. Med Pediatr Oncol 1976;2:119–76.

2. Van Der Does-Van Den Berg A., Van Wering E.R., Van Zanen C.E. Acute nietlympfatischen leukemieen bij kinderen in Nederland (1972-1977). Tijdschr Kindergeneeskd 1978;46:146–53.

3. Chard Jr. Rl., Frankleshtein J.Z., Sonley M.J. et al. Increased survival in childhood nonlymphocytic leukemia after treatment with prednisone cytosine arabinoside, 6-thioguanine, cyclophosphomide, and oncovin (PATCO) combination chemotherapy. Med Pediatr Oncol 1978;4:263–73.

4. Weinshtein H.J., Mayer R.J., Rosental D.S. et al. Treatment of acute myelogenous leukemia in children and adults. N Engl J Med 1980;303:473–8.

5. Riehm H., Gadner H., Welte K. Die West-Berliner Studie zur Behanlung der akuten lymphoblastishen Leukamie des Kindes – Erfandlungsbericht nach 6 Jahren. Klin Padiatr 1977;189:89–102.

6. Baehner R.J., Bernstein I.D., Sather et al. Improved remission induction rate D-ZAPO but unimproved remission duration with addition of immutherapy to chemotherapy in previously untreated children with ANLL. Med Pediatr Oncol 1979;7:127–39.

7. Buchner T., Urbanitz D., Hiddemann W. et al. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of German AML Cooperative Group. J Clin Oncol 1985;3:1583–9.

8. Creutzig U., Zimmermann M., Ritter J. et al. Treatment strategies and longterm in pediatric patients treated in four consecutive AML-BFM trails. Leukemia 2005;19:2039–42.

9. Carella A.M., Berman E., Maraone M.P., Ganzina F. An overview of preclinical and clinical studies. Hematologica 1990;75:159–69.

10. Berman E., McBride M.. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 1992;79:3267–73.

11. Creutzig U., Ritter J., Zimmermann M. et al. for the BFM study group. Idarubicine improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. Leukemia 2001;15:348–54.

12. Creutzig U., Berhold F., Boos J. et al. Improved treatment results in children with AML: results of study AML-BFM 93. Klin Pediatr 2001;213:175–85.

13. Creutzig U., Ritter J., Schelong G. Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in the study AMLBFM-83 as a compared with study AMLBFM-78. Blood 1990;75:1932–40.

14. Gibson B.E.S., Wheatley K., Hann I.M. et al. Treatment strategy and longterm results in pediatric patients treated in consecutive UK AML trais. Leukemia 2005;19:2130–8.

15. Perel Y., Auvrignon A., Leblanc T. et al. Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no beneit – multicenter studies of the French LAME (Leucemie Aiguё Myelobalstique Enfant) Cooperative Group. Leukemia 2005;19:2082–9.

16. Smith O., Alonzo T.A., Gerbing R.B. et al. Long-term results of children with acute myeloid leukemia: report of three consecutive Phase III trails by the Children’s Cancer Group: CCG 251, CCG 213 and CCG 2891. Leukemia 2005;19 – pp. 2054–62.

17. Wells R.J., Woods W.G., Buckley J.D. et al. Treatment of newly diagnosed children and adolescents with acute myeloid leukemia: a Children’s cancer Group study. J Clin Oncol 1994;12:2367–77.

18. Woods W.G., Kobrinsky N., Buckley J.D. et al. Timed sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from Children’s Cancer Group. Blood 1996;87: 4979–89.

19. Woods W.G., Neudorf S., Gold S. et al. A comparison of allogenic bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: a report from Children’s Cancer Group. Blood 2001;97: 56–62.

20. Ribeiro R.C., Razzouk B.I., Pounds S. et al. Successive clinical trails for childhood acute myeloid leukemia at St Jude Children’s Research Hospital, from 1980 to 2000. Leukemia 2005;19:2125–9.

21. Попа А.В., Маякова С.А., Тупицын Н.Н. Прогностическое значение иммунологических маркеров острого нелимфобластного лейкоза у детей. Педиатрия 1999;(3).

22. Попа А.В., Маякова С.А., Тупицын Н.Н. Результаты лечения детей, больных острым миелоидным лейкозом, в зависимости от иммунофенотипа бластных клеток. Гематол и трансфузиол 1999;(6).

23. Abbott B.L, Rubnitz J.E., Tong X. et al. Clinical significance of central of central nervous system involvement at diagnosis of pediatric acute myeloid leukemia: a single institution’s experience. Leukemia 2003;17:2090–6.

24. Creutzig U., Zimmermann M., Reinhardt D. et al. Early death and treatment related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trails AML-BFM 93 and AML-BFM 98. J Clin Oncol 2004;22:4384–93.

25. Lehnbecher T., Varwig D., Kaiser J. et al. Infectious complications in pediatric acute myeloid leukemia: analisis of the prospective multi-institutional clinical trail AML-BFM 93. Leukemia 2004;18:72–7.

26. Slats A.M., Egeler R.M., Van Der Does-Van den Berg A. et al. Causes of death other then progressive leukemia in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experience. Leukemia 2005;19:537–44.

27. Creutzig U., Reinhardt D. Currant controversies: which patients with acute myeloid leukemia should receive a bone marrow transplantation? A European view. Br J Hematol 2002;118:365–77.

28. Chen A.R., Alonzo T.A., Woods W.G., Arceci R.J. Currant controversies: which patients with acute myeloid leukemia should receive a bone marrow transplantation? An American view. Br J Hematol 2002;118:378–84.

29. Whealthy K. Currant controversies: which patients with acute myeloid leukemia should receive a bone marrow transplantation? A statistician view. Br J Hematol 2002;118:351–56.